Evaluation and optimization of medication in seniors with polypharmacy and multimorbidity. Clinical guidelines of the Board of the Czech Society of Gerontology and Geriatrics, Czech Medical Association JEP

Česká verzia

Authors: Topinková Eva ¹; Vaňková Hana ²; Šnajdrová Zuzana ³; Matějková Astrid ⁴; Jurašková Božena ⁵
Authors place of work: Geriatrická klinika 1. lékařské fakulty Univerzity Karlovy v Praze a Všeobecné fakultní nemocnice v Praze ¹; Interní klinika 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady ²; Nemocnice Milosrdných sester sv. K. Boromejského v Praze ³; Geriatrické centrum, Pardubická nemocnice ⁴; III. interní gerontometabolická klinika Fakultní nemocnice Hradec Králové, Subkatedra geriatrie Lékařské fakulty v Hradci Králové, Univerzita Karlova ⁵
Published in the journal: Geriatrie a Gerontologie 2024, 13, č. 1: 32-37
Category:

Summary

Population aging, multimorbidity and polypharmacy increase the risk of medication-related harm. Improving patients’ safety, optimization, and rational prescribing aiming to decrease health care costs pose a new challenge for geriatric medicine. Comprehensive evaluation of medication and rational and safe prescribing in senior with high risk of adverse medication events, polypharmacy and chronic multimorbidity in the context of additional geriatric syndromes has a proven benefit for the safety of pharmacological treatment, health and functional status of seniors and decreased costs for health care.

Presented Clinical guidelines for performing the evaluation and optimization of medication in seniors with polypharmacy and multimorbidity describe the content and methodology of the procedure. These clinical guidelines were developed and approved by the Board of the Czech Society of Gerontology and Geriatrics, CMA JEP based on international guidelines and currently are being recommended as a novel health procedure for the geriatric medicine specialty for the Ministry of Health Czech Republic approval.

Keywords:

clinical guidelines, optimization of pharmacotherapy, geriatric patient, polypharmacy, mul-timorbidity

Zdroje

1. Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med 2021; 12(3): 443–452.

2. Global Patient Safety Challenge: Medication Without Harm. WHO Global Patient Safety Challenge. WHO 2017. Dostupné z: www.who.int/publications/i/item/WHO-HIS-SDS-2017.6

3. Parekh N, Ali K, Stevenson JM, Davies G, et al. Frailty predicts medication-related harm requiring healthcare: a UK multicentre prospective cohort study. Age Ageing 2019; 48: i27–30.

4. Cullinan S, O’Mahony D, O’Sullivan D, et al. Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients. Age Ageing 2016; 45: 115–120.

5. Osanlou R, Walker L, Hughes DA, et al. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open 2022; 12(7): e055551.

6. Gallagher P, Lang PO, Cherubini A, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol 2011; 67: 1175–1188.

7. Petrovic M, O‘Mahony D, Cherubini A. Inappropriate prescribing: hazards and solutions. Age Ageing 2022.

8. Bülow C, Clausen SS, Lundh A, et al. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev 2023 23; 1(1): CD008986.

9. van Poelgeest E, Seppala L, Bahat G, et al. EuGMS SIG Pharmacology. Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper. Eur Geriatr Med 2023; 14(6): 1195–1209.

10. Onder G, Vetrano DL, Palmer K, et al. Italian guidelines on management of persons with multimorbidity and polypharmacy. Aging Clin Exp Res 2022; 34(5): 989–996.

11. Reeve E, Thompson W, Farrell B. Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med 2017; 38: 3–11.

12. Mangin D, Bahat G, Golomb BA, et al. International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): position statement and 10 recommendations for action. Drug Aging 2018; 35(7): 575–587.

13. NICE. Medicines management in care homes. Quality standard [QS85]. https://www.nice.org.uk/guidance/qs85S3-Leitlinie „Demenzen“ (Langversion). Deutsche Gesellschaft für Neurologie und Deutsche Gesellschaft für Psychiatrie und Psychotherapie 2023. Dostupné z: https://dnvp9c1uo2095.cloudfront.net/cms-content/S3.

14. Leitlinie_Demenzen_Langversion_2023_11_28_Final_1701248604534.pdf.

15. Topinková E, Fialová D. Doporučené nástroje pro revizi medikace a optimalizaci preskripce u geriatrických pacientů. Geri Gero 2023; 12(3): 114–126.

16. Topinková E, Fialová D. Nová verze STOPP-START kritérií 2023 jako vhodný nástroj ke zlepšení lékové preskripce u starších pacientů. Vnitř Lék 2023; 69(8): 516–524.

17. Topinková E. Racionální a bezpečná preskripce u starších nemocných s pády a pokročilou křehkostí. Akt Med 2023; 2: 36–41.

18. Van Poelgeest EP, et al. Deprescribing practices, habits and attitudes of geriatricians and geriatricians-in-training across Europe: a large web-based survey. Eur Ger Med 2022; 13(6): 1455–1466.

19. Hill-Taylor B, Walsh KA, Stewart S, et al. Effectiveness of the STOPP/START (Screening Tool of Older Persons’ potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther 2016; 41: 158–169.

20. O’Mahony D, Gudmundsson A, Soiza RL, et al. Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR randomized controlled clinical trial. Age Ageing 2020; 49(4): 605–614.

21. Blum MR, Sallevelt BTGM, Spinewine A, et al. Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ 2021; 374: 1585.

22. Mair A, Kirke C, Scott M, et al. iSIMPATHY Evaluation Report. Edinburgh iSIMPATHY Consortium 2023.

23. Beuscart JB, Pelayo S, Robert L, et al. Medication review and reconciliation in older adults. Eur Geriatr Med 2021; 12(3): 499–507.

24. Scottish Government Polypharmacy Model of Care Group. 2018 Polypharmacy guidance: Realistic prescribing. 3rd edition. Dostupné z https://www.therapeutics.scot.nhs.
uk/wp-content /uploads/2018/09/Polypharmacy-Guidance-2018.pdf.

25. Fialová D, Topinková E, Ballóková A, et al. Expertní konsenzus ČR 2012 v oblasti léčiv a lékových postupů potenciálně nevhodných ve stáří. Klin Farmakol Farm 2013; 27(1): 18–28.

26. O’Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med 2023; 14(4): 625–632.

27. Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) List 2021: Fourth version of a validated clinical aid for improved pharmacotherapy in older adults. Drugs Aging 2022; 39(3): 245–247. Erratum in: Drugs Aging 2022; 39(6): 485.

28. Pazan F, Weiss C, Wehling M. FORTA Expert Panel Members. The EURO-FORTA (Fit fOR The Aged) List Version 2: Consensus validation of a clinical tool for improved pharmacotherapy in older adults. Drugs Aging 2023; 40(5): 417–426.

29. By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2023, May 4.

30. Seppala LJ, Petrovic M, Ryg J, et al. STOPP Fall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS task and finish group on fall-risk-increasing drugs. Age Ageing 2020; 1–11.

31. Curtin D, Gallagher P, O’Mahony D. Deprescribing in older people approaching end-of-life: development and validation of STOPP Frail version 2. Age Ageing 2021; 50(2): 465–471.

32. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Med Arch Intern 2008; 168(5): 508–513.

33. Topinková E. Redukce nevhodné a neúčelné farmakoterapie – deprescribing. Geri a Gero 2020; 9(1): 9–14.